USFDA completes audit of contract manufacturing facility of Jubilant Pharmova Montreal unit
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Nadda expressed his concern about growing incidence of Non-Communicable Diseases and the importance of awareness regarding healthy diet and lifestyle
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Subscribe To Our Newsletter & Stay Updated